Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.73 USD
Change Today +0.10 / 1.78%
Volume 91.0K
AKAO On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 5:20 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

achaogen inc (AKAO) Snapshot

Open
$5.64
Previous Close
$5.63
Day High
$5.93
Day Low
$5.55
52 Week High
06/20/14 - $17.31
52 Week Low
05/12/15 - $5.30
Market Cap
103.4M
Average Volume 10 Days
222.8K
EPS TTM
$-1.28
Shares Outstanding
18.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACHAOGEN INC (AKAO)

Related News

No related news articles were found.

achaogen inc (AKAO) Related Businessweek News

No Related Businessweek News Found

achaogen inc (AKAO) Details

Achaogen, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States. The company is principally developing plazomicin, which is in Phase III combating antibiotic resistant enterobacteriaceae trials for the treatment of bacterial infections due to multi-drug resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds that target infections caused by acinetobacter baumannii and pseudomonas aeruginosa. The company was incorporated in 2002 and is headquartered in South San Francisco, California.

44 Employees
Last Reported Date: 05/11/15
Founded in 2002

achaogen inc (AKAO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $380.1K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $270.0K
Chief Medical Officer
Total Annual Compensation: $244.4K
Vice President of Finance and Corporate Devel...
Total Annual Compensation: $248.1K
Compensation as of Fiscal Year 2014.

achaogen inc (AKAO) Key Developments

Achaogen, Inc. Announces Executive Changes

Achaogen, Inc. announced the appointments of Dr. Alan Colowick and Dr. Kent Lieginger to its Board of Directors. Dr. Colowick has held senior managerial positions at large and emerging biotechnology companies. Most recently at Celgene Corporation, he served as President for the Europe, Mid-East, and Africa region from 2012 to 2014 and Senior Vice President Global Medical Affairs from 2010 to 2012. Dr. Lieginger was most recently Senior Vice President, Managed Care and Customer Operations at Genentech, Inc., as well as Director of the Genentech Foundation since 2005. He originally joined Genentech as Vice President, Managed Care and Customer Operations in 2004 and served as a member of Genentech's Commercial Leadership Committee.

Achaogen, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Achaogen, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported contract revenue of $4,880,000 against $5,988,000 a year ago. The company derived all of its revenue from funding provided under U.S. government contracts in connection with the development of product candidates. Loss from operations was $6,230,000 against $3,234,000 a year ago. Net loss was $6,179,000 against $3,455,000 a year ago. Basic and diluted net loss per common share was $0.34 against $1.00 a year ago.

Achaogen, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 01:40 PM

Achaogen, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 01:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Kenneth J. Hillan, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKAO:US $5.73 USD +0.10

AKAO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKAO.
View Industry Companies
 

Industry Analysis

AKAO

Industry Average

Valuation AKAO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.4x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHAOGEN INC, please visit www.achaogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.